Revelation Biosciences
Revelation Biosciences, founded in 2020, focuses on developing therapies for disease prevention and treatment through trained immunity, utilizing its Gemini formulation.
Founders
Revelation Biosciences was founded in 2020 by industry veterans with a proven track record of successful drug development. The founders have considerable experience in creating therapies and this expertise is a core asset for the company's strategic and operational success.
Product Candidates
Revelation Biosciences develops therapies for the prevention and treatment of disease using trained immunity. Their product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The ongoing programs include GEMINI-SSI, which focuses on post-surgical infection prevention, GEMINI-AKI for acute kidney injury prevention, and GEMINI-CKD for the treatment of chronic kidney disease.
Ongoing Programs
Revelation Biosciences is evaluating the Gemini formulation of PHAD across multiple programs. These include GEMINI-SSI for preventing post-surgical infections, GEMINI-AKI for preventing acute kidney injury, and GEMINI-CKD for treating chronic kidney disease. Multiple nonclinical studies have been conducted, showcasing the therapeutic potential of Gemini in these target indications.
Clinical Study Plans
Revelation Biosciences plans to initiate clinical studies in 2023. These studies aim to further demonstrate the effectiveness and safety of their Gemini formulation of PHAD in preventing and treating various medical conditions.